Mucormycosis Treatment Market, By Species (Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, Mucor, Lichtheimia, Apophysomyces And Others), By Diagnosis Method (Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy And Others.), By Treatment (Amphotericin B Therapy, Antifungal Medication, Surgery, And Others), By End-User, (Hospitals, Clinics, Research Organization, Medical Institute And Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI469121 | Publish Date: August 2023 | No. of Pages: 168

Global Mucormycosis Treatment Market Companies

  • Abbott Laboratories
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Novartis AG
  • F. Hoffman La Roche
  • Merck Sharp and Dohme
  • Mylan Labs
  • Bristol Myers Squibb
  • Bayer AG
  • Lonza Group
  • Sanofi
  • Johnson & Johnson
  • Pfizer Inc.
  • Gilead Sciences.

Recent News:

  • In October 2023, the first-ever generic medication, Zisavel Capsules, was introduced by BDR Pharmaceutical to treat invasive aspergillosis and mucormycosis. Zisavel is a member of the azole antifungals (AZO) drug class, which also includes isavuconazole. One of the mainstays of treatment for invasive aspergillosis is isavuconazole.